Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2017 Earnings Presentation
16 slides from Dr. Lal Pathlabs's earnings presentation, May 12, 2017
Slide 1: Dr. Lal PathLabs Limited (DLPL) Q4 & FY17 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 & FY17 Results Presentation May 12, 2017
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q4 & FY2017 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. Th
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 189 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,759 Patient Service diagnostic services Centers (PSCs) and 5,021 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Growth is gradually normalising post demonetisation with volume trajectory showing improvement QoQ During Q4 FY17 : Revenues showed 11.3% increase at Rs. 2199 million owing to sustained volume growth of 7.7% in Q4 Normalised EBITDA (after eliminating the impact of ESOP/other s
Slide 5: Q4 & FY17 Financial Performance
Q4 & FY17 Financial Performance Particulars (Rs. mn) Q4 FY17 Q4FY16 Growth % FY17 FY16 Growth % Revenues 2,199.0 1,977.1 11.2% 9,123.8 7,913.2 15.3% Total Expenditure 1,705.5 1,435.8 18.8% 6,758.4 5,816.0 16.2% EBITDA 493.5 541.3 (8.8)% 2365.4 2097.2 12.8% ESOP/ ESPS/ RSU charges 26.0 (15.4) - 80.5
Slide 6: Financial Highlights: Revenues
Financial Highlights Revenues All figures in Rs mn 2,622 9,124 2,228 2,199 2,075 7,913 1,977 Q4FY16 Q1FY17 Q2FY17 Q3FY17 Q4FY17 FY16 FY17 Q4 FY17 revenues reported 11.3% growth on the back of expansion in volumes by 7.7% YoY. Improvement in business momentum QoQ indicates: • Increased footprint of
Slide 7: Financial Highlights: Normalised EBITDA
Financial Highlights All figures in Rs mn Normalised EBITDA excl stock based cost and CSR expense 529 538 2,465 2,110 Q4 FY16 Q4 FY17 FY16 FY17 During Q4FY17 the growth in normalised EBITDA (after eliminating the impact of stock based cost and CSR expenses) stood moderated at 1.8% on account of; •
Slide 8: Financial Highlights: PBT
Financial Highlights All figures in Rs mn PBT 2,333 528 475 2,007 Q4FY16 Q4FY17 FY16 FY17 FY17 PBT growth was at 16.2% at Rs. 2,332.9 million; PBT during Q4 was at Rs. 474.6 million Similarly full-year expansion in PAT was recorded at 16.5% at Rs 1552 mn. PAT margin stood improved at 17% from 16
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,759 5,668 1,559 4,967 5,021 189 1,340 4,225 172 164 1,064 146 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 No. of patients (mn) No. of samples (mn) 29.3 13.3 26.3 12.0 21.7 19.0 9.9 9.0 FY14 FY15 FY16 FY17 FY1
Slide 10: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “Our performance in FY17 illustrated that our strategy to deliver a complete scope of diagnostic solutions is working well and encourages us to strive for more. Our sustained and pragm
Slide 11: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 12: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 12
Slide 13: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 13
Slide 14: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 15: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer COO (Strategic Business Unit 1) COO –
Slide 16: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests an